Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 in children and adolescents with 22q11.2 Deletion Syndrome
NCT05149898Phase 2Completed
- Sponsor
- Harmony Biosciences
- Start
- Feb 2020
- Primary completion
- Nov 2022
- Countries
- 2
01
Overview
Phase 2, open-label trial of Zygel in 22q11.2 deletion syndrome (22qDS), sponsored by Harmony Biosciences. Primary endpoint: Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events at 306 days. Started Feb 2020; status: completed.
02
Drugs
Zygel
03
Conditions
22q11.2 deletion syndrome (22qDS)
Beyond the preview
Go deeper on NCT05149898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05149898.